Infections are the leading cause of death for individuals with traumatic spinal cord injury (SCI). Along with increased infection rates, inflammation is often also observed in persons with chronic SCI. Together, immunological changes post-SCI are also poised to impede neurological recovery and mediate common medical consequences of SCI, including atherogenesis and neuropathic pain. The molecular mechanisms contributing to increased infection susceptibility and inflammation in persons living with SCI are poorly understood. Here, we used tools of functional genomics to perform a pilot study to compare whole-blood gene expression in individuals with chronic SCI (≥1 year from initial injury; N = 31) and uninjured individuals (N = 26). We identified 1815 differentially expressed genes in all SCI participants and 2226 differentially expressed genes in persons with SCI rostral to thoracic level 5, compared to uninjured participants. This included marked downregulation of natural killer cell genes and upregulation of the proinflammatory Toll-like receptor signaling pathway. These data provide novel mechanistic insights into the causes underlying the symptoms of immune dysfunction in individuals living with SCI.
Get full access to this article
View all access options for this article.
References
1.
National Spinal Cord Injury Statistical Center. (2017). Facts and Figures at a Glance. University of Alabama at Birmingham: Birmingham, AL.
2.
National Spinal Cord Injury Statistical Center. (2016). 2016 Annual Statistical Report for the Spinal Cord Injury Model Systems Public Version, in: Complete Public Version. University of Alabama at Birmingham: Birmingham, AL.
3.
DeVivoM.J., BlackK.J., and StoverS.L. (1993). Causes of death during the first 12 years after spinal cord injury. Arch. Phys. Med. Rehabil., 74, 248–254.
4.
CardenasD.D., HoffmanJ.M., KirshblumS., and McKinleyW. (2004). Etiology and incidence of rehospitalization after traumatic spinal cord injury: a multicenter analysis. Arch. Phys. Med. Rehabil., 85, 1757–1763.
5.
DeJongG., TianW., HsiehC.H., JunnC., KaramC., BallardP.H., SmoutR.J., HornS.D., ZancaJ.M., HeinemannA.W., HammondF.M., and BackusD. (2013). Rehospitalization in the first year of traumatic spinal cord injury after discharge from medical rehabilitation. Arch. Phys. Med. Rehabil., 94, 4 Suppl., S87–S97.
PopovichP., and McTigueD. (2009). Damage control in the nervous system: beware the immune system in spinal cord injury. Nat. Med., 15, 736–737.
16.
BankM., SteinA., SisonC., GlazerA., JassalN., McCarthyD., ShatzerM., HahnB., ChughR., DaviesP., and BloomO. (2015). Elevated circulating levels of the pro-inflammatory cytokine macrophage migration inhibitory factor in individuals with acute spinal cord injury. Arch. Phys. Med. Rehabil., 96, 633–644.
17.
KwonB.K., StammersA.M., BelangerL.M., BernardoA., ChanD., BishopC.M., SlobogeanG.P., ZhangH., UmedalyH., GiffinM., StreetJ., BoydM.C., PaquetteS.J., FisherC.G., and DvorakM.F. (2010). Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. J. Neurotrauma, 27, 669–682.
18.
KwonB.K., StreijgerF., FallahN., NoonanV.K., BelangerL.M., RitchieL., PaquetteS.J., AilonT., BoydM.C., StreetJ., FisherC.G., and DvorakM.F. (2017). Cerebrospinal fluid biomarkers to stratify injury severity and predict outcome in human traumatic spinal cord injury. J. Neurotrauma, 34, 567–580.
19.
PapatheodorouA., SteinA., BankM., SisonC.P., GibbsK., DaviesP., and BloomO. (2017). High-mobility group box 1 (HMGB1) is elevated systemically in persons with acute or chronic traumatic spinal cord injury. J. Neurotrauma, 34, 746–754.
20.
PouwM.H., KwonB.K., VerbeekM.M., VosP.E., van KampenA., FisherC.G., StreetJ., PaquetteS.J., DvorakM.F., BoydM.C., HosmanA.J., and van de MeentH. (2014). Structural biomarkers in the cerebrospinal fluid within 24 h after a traumatic spinal cord injury: a descriptive analysis of 16 subjects. Spinal Cord, 52, 428–433.
21.
StreijgerF., SkinniderM.A., RogalskiJ.C., BalshawR., ShannonC.P., PrudovaA., BelangerL., RitchieL., TsangA., ChristieS., ParentS., Mac-ThiongJ.M., BaileyC., UrquhartJ., AilonT., PaquetteS., BoydM., StreetJ., FisherC.G., DvorakM.F., BorchersC.H., FosterL.J., and KwonB.K. (2017). A targeted proteomics analysis of cerebrospinal fluid after acute human spinal cord injury. J. Neurotrauma, 34, 2054–2068.
22.
DaviesA.L., HayesK.C., and DekabanG.A. (2007). Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury. Arch. Phys. Med. Rehabil., 88, 1384–1393.
23.
FrostF., RoachM.J., KushnerI., and SchreiberP. (2005). Inflammatory C-reactive protein and cytokine levels in asymptomatic people with chronic spinal cord injury. Arch. Phys. Med. Rehabil., 86, 312–317.
24.
SegalJ.L., GonzalesE., YousefiS., JamshidipourL., and BrunnemannS.R. (1997). Circulating levels of IL-2R, ICAM-1, and IL-6 in spinal cord injuries. Arch. Phys. Med. Rehabil., 78, 44–47.
25.
SteinA., PanjwaniA., SisonC., RosenL., ChughR., MetzC., BankM., and BloomO. (2013). Pilot study: elevated circulating levels of the proinflammatory cytokine macrophage migration inhibitory factor in patients with chronic spinal cord injury. Arch. Phys. Med. Rehabil., 94, 1498–1507.
26.
GarshickE., StolzmannK.L., GagnonD.R., MorseL.R., and BrownR. (2011). Systemic inflammation and reduced pulmonary function in chronic spinal cord injury. PM R. 3, 433–439.
27.
BaumanW.A., and SpungenA.M. (1994). Disorders of carbohydrate and lipid metabolism in veterans with paraplegia or quadriplegia: a model of premature aging. Metabolism, 43, 749–756.
28.
BaumanW.A., KahnN.N., GrimmD.R., and SpungenA.M. (1999). Risk factors for atherogenesis and cardiovascular autonomic function in persons with spinal cord injury. Spinal Cord, 37, 601–616.
29.
BaumanW.A., and SpungenA.M. (2000). Metabolic changes in persons after spinal cord injury. Phys. Med. Rehabil. Clin. N. Am., 11, 109–140.
30.
PavlovV.A,. and TraceyK.J. (2012). The vagus nerve and the inflammatory reflex–linking immunity and metabolism. Nat. Rev. Endocrinol., 8, 743–754.
31.
PavlovV.A., and TraceyK.J. (2017). Neural regulation of immunity: molecular mechanisms and clinical translation. Nat. Neurosci., 20, 156–166.
32.
ZimmerP., SchenkA., KievenM., HolthausM., LehmannJ., LovenichL., and BlochW. (2017). Exercise induced alterations in NK-cell cytotoxicity—methodological issues and future perspectives. Exerc. Immunol. Rev., 23, 66–81.
33.
LeichtC.A., Goosey-TolfreyV.L., and BishopN.C. (2013). Spinal cord injury: known and possible influences on the immune response to exercise. Exerc. Immunol. Rev., 19, 144–163.
34.
NashM.S. (1994). Immune responses to nervous system decentralization and exercise in quadriplegia. Med. Sci. Sports Exerc., 26, 164–171.
35.
CampagnoloD.I., KellerS.E., DeLisaJ.A., GlickT.J., SipskiM.L., and SchleiferS.J. (1994). Alteration of immune system function in tetraplegics. A pilot study. Am. J. Phys. Med. Rehabil., 73, 387–393.
36.
CampagnoloD.I., DixonD., SchwartzJ., BartlettJ.A., and KellerS.E. (2008). Altered innate immunity following spinal cord injury. Spinal Cord, 46, 477–481.
37.
SaltzmanJ.W., BattaglinoR.A., SallesL., JhaP., SudhakarS., GarshickE., StottH.L., ZafonteR., and MorseL.R. (2013). B-cell maturation antigen, a proliferation-inducing ligand, and B-cell activating factor are candidate mediators of spinal cord injury-induced autoimmunity. J. Neurotrauma, 30, 434–440.
38.
BenjaminiY., and HochbergY. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B, 57, 289–300.
39.
ChaussabelD., and BaldwinN. (2014). Democratizing systems immunology with modular transcriptional repertoire analyses. Nat. Rev. Immunol., 14, 271–280.
WatkinsN.A., GusnantoA., de BonoB., DeS., Miranda-SaavedraD., HardieD.L., AngenentW.G., AttwoodA.P., EllisP.D., ErberW., FoadN.S., GarnerS.F., IsackeC.M., JolleyJ., KochK., MacaulayI.C., MorleyS.L., RendonA., RiceK.M., TaylorN., Thijssen-TimmerD.C., TijssenM.R., van der SchootC.E., WernischL., WinzerT., DudbridgeF., BuckleyC.D., LangfordC.F., TeichmannS., GottgensB., OuwehandW.H., and BloodomicsC. (2009). A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood, 113, e1–e9.
42.
GaujouxR., and SeoigheC. (2013). CellMix: a comprehensive toolbox for gene expression deconvolution. Bioinformatics, 29, 2211–2212.
43.
ChenE.Y., TanC.M., KouY., DuanQ., WangZ., MeirellesG.V., ClarkN.R., and Ma'ayanA. (2013). Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics, 14, 128.
44.
ArduraM.I., BanchereauR., MejiasA., Di PucchioT., GlaserC., AllantazF., PascualV., BanchereauJ., ChaussabelD., and RamiloO. (2009). Enhanced monocyte response and decreased central memory T cells in children with invasive Staphylococcus aureus infections. PLoS One, 4, e5446.
45.
BanchereauR., Jordan-VillegasA., ArduraM., MejiasA., BaldwinN., XuH., SayeE., Rossello-UrgellJ., NguyenP., BlankenshipD., CreechC.B., PascualV., BanchereauJ., ChaussabelD., and RamiloO. (2012). Host immune transcriptional profiles reflect the variability in clinical disease manifestations in patients with Staphylococcus aureus infections. PLoS One, 7, e34390.
46.
KiddB.A., PetersL.A., SchadtE.E., and DudleyJ.T. (2014). Unifying immunology with informatics and multiscale biology. Nat. Immunol., 15, 118–127.
47.
Shen-OrrS.S., and GaujouxR. (2013). Computational deconvolution: extracting cell type-specific information from heterogeneous samples. Curr. Opin. Immunol., 25, 571–578.
48.
SatzerD., MillerC., MaxonJ., VothJ., DiBartolomeoC., MahoneyR., DuttonJ.R., LowW.C., and ParrA.M. (2015). T cell deficiency in spinal cord injury: altered locomotor recovery and whole-genome transcriptional analysis. BMC Neurosci. 16, 74.
49.
BerryM.P., GrahamC.M., McNabF.W., XuZ., BlochS.A., OniT., WilkinsonK.A., BanchereauR., SkinnerJ., WilkinsonR.J., QuinnC., BlankenshipD., DhawanR., CushJ.J., MejiasA., RamiloO., KonO.M., PascualV., BanchereauJ., ChaussabelD., and O'GarraA. (2010). An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature, 466, 973–977.
50.
ObermoserG., PresnellS., DomicoK., XuH., WangY., AnguianoE., Thompson-SnipesL., RanganathanR., ZeitnerB., BjorkA., AndersonD., SpeakeC., RuchaudE., SkinnerJ., AlsinaL., SharmaM., DutartreH., CepikaA., IsraelssonE., NguyenP., NguyenQ.A., HarrodA.C., ZurawskiS.M., PascualV., UenoH., NepomG.T., QuinnC., BlankenshipD., PaluckaK., BanchereauJ., and ChaussabelD. (2013). Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity, 38, 831–844.
51.
LiP., WangB., SunF., LiY., LiQ., LangH., ZhaoZ., GaoP., ZhaoY., ShangQ., LiuD., and ZhuZ. (2015). Mitochondrial respiratory dysfunctions of blood mononuclear cells link with cardiac disturbance in patients with early-stage heart failure. Sci. Rep., 5, 10229.
52.
IwasakiA., and MedzhitovR. (2004). Toll-like receptor control of the adaptive immune responses. Nat. Immunol., 5, 987–995.
53.
KanzlerH., BarratF.J., HesselE.M., and CoffmanR.L. (2007). Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med., 13, 552–559.
54.
Adib-ConquyM., Scott-AlgaraD., CavaillonJ.M., and Souza-Fonseca-GuimaraesF. (2014). TLR-mediated activation of NK cells and their role in bacterial/viral immune responses in mammals. Immunol. Cell Biol., 92, 256–262.
55.
Souza-Fonseca-GuimaraesF., ParlatoM., PhilippartF., MissetB., CavaillonJ.M., and Adib-Conquy, M.; Captain study group. (2012). Toll-like receptors expression and interferon-gamma production by NK cells in human sepsis. Crit. Care, 16, R206.
56.
DarwicheS.S., RuanX., HoffmanM.K., ZettelK.R., TracyA.P., SchroederL.M., CaiC., HoffmanR.A., ScottM.J., PapeH.C., and BilliarT.R. (2013). Selective roles for toll-like receptors 2, 4, and 9 in systemic inflammation and immune dysfunction following peripheral tissue injury. J. Trauma Acute Care Surg., 74, 1454–1461.
57.
LiX.Q., LvH.W., TanW.F., FangB., WangH., and MaH. (2014). Role of the TLR4 pathway in blood-spinal cord barrier dysfunction during the bimodal stage after ischemia/reperfusion injury in rats. J. Neuroinflammation, 11, 62.
58.
KigerlK.A., and PopovichP.G. (2009). Toll-like receptors in spinal cord injury. Curr. Top. Microbiol. Immunol., 336, 121–136.
59.
KigerlK.A., LaiW., RivestS., HartR.P., SatoskarA.R., and PopovichP.G. (2007). Toll-like receptor (TLR)-2 and TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury. J. Neurochem., 102, 37–50.
60.
StirlingD.P., CumminsK., MishraM., TeoW., YongV.W., and StysP. (2014). Toll-like receptor 2-mediated alternative activation of microglia is protective after spinal cord injury. Brain, 137, 707–723.
61.
StiversN.S., PelischN., OremB.C., WilliamsJ., NallyJ.M., and StirlingD.P. (2017). The toll-like receptor 2 agonist Pam3CSK4 is neuroprotective after spinal cord injury. Exp. Neurol., 294, 1–11.
62.
ChurchJ.S., KigerlK.A., LerchJ.K., PopovichP.G., and McTigueD.M. (2016). TLR4 deficiency impairs oligodendrocyte formation in the injured spinal cord. J. Neurosci., 36, 6352–6364.
63.
KigerlK.A., LaiW., WallaceL.M., YangH., and PopovichP.G. (2017). High mobility group box-1 (HMGB1) is increased in injured mouse spinal cord and can elicit neurotoxic inflammation. Brain Behav. Immun. 2017Nov23. pii: S0889-1591(17)30519-6. doi:10.1016/j.bbi.2017.11.018. [Epub ahead of print]
64.
DidangelosA., PugliaM., IberlM., Sanchez-BellotC., RoschitzkiB., and BradburyE.J. (2016). High-throughput proteomics reveal alarmins as amplifiers of tissue pathology and inflammation after spinal cord injury. Sci. Rep., 6, 21607.
65.
YuanZ., LuoG., LiX., ChenJ., WuJ., and PengY. (2016). PPARgamma inhibits HMGB1 expression through upregulation of miR-142-3p in vitro and in vivo. Cell. Signal., 28, 158–164.
66.
GaoM., HuZ., ZhengY., ZengY., ShenX., ZhongD., and HeF. (2011). Peroxisome proliferator-activated receptor gamma agonist troglitazone inhibits high mobility group box 1 expression in endothelial cells via suppressing transcriptional activity of nuclear factor kappaB and activator protein 1. Shock, 36, 228–234.
67.
GleesonM., BishopN.C., StenselD.J., LindleyM.R., MastanaS.S., and NimmoM.A. (2011). The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol., 11, 607–615.
68.
SabharwalL., KamimuraD., MengJ., BandoH., OguraH., NakayamaC., JiangJ.J., KumaiN., SuzukiH., AtsumiT., ArimaY., and MurakamiM. (2014). The Gateway Reflex, which is mediated by the inflammation amplifier, directs pathogenic immune cells into the CNS. J. Biochem., 156, 299–304.
69.
LustigA., LiuH.B., MetterE.J., AnY., SwabyM.A., ElangoP., FerrucciL., HodesR.J., and WengN.P. (2017). Telomere shortening, inflammatory cytokines, and anti-cytomegalovirus antibody follow distinct age-associated trajectories in humans. Front. Immunol., 8, 1027.
70.
KesingerM.R., KumarR.G., WagnerA.K., PuyanaJ.C., PeitzmanA.P., BilliarT.R., and SperryJ.L. (2015). Hospital-acquired pneumonia is an independent predictor of poor global outcome in severe traumatic brain injury up to 5 years after discharge. J. Trauma Acute Care Surg., 78, 396–402.
71.
KumarR.G., BolesJ.A,. and WagnerA.K. (2015). Chronic inflammation after severe traumatic brain injury: characterization and associations with outcome at 6 and 12 months postinjury. J. Head Trauma Rehabil., 30, 369–381.
72.
MeiselC., SchwabJ.M., PrassK., MeiselA., and DirnaglU. (2005). Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci, 6, 775–786.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
